Virbac S.A. Stock
€336.50
Your prediction
Virbac S.A. Stock
Pros and Cons of Virbac S.A. in the next few years
Pros
Cons
Performance of Virbac S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Virbac S.A. | -1.610% | 0.146% | 10.145% | -6.430% | 9.615% | -1.441% | 76.107% |
| Onxeo S.A. | -2.550% | 7.843% | -15.902% | -44.612% | -33.655% | -82.919% | -92.165% |
| Boiron S.A. | -0.670% | 0.449% | -2.402% | -28.480% | -16.292% | -49.205% | -42.912% |
| Nicox S.A. | 30.050% | 0.000% | 5.263% | 24.224% | -22.330% | -89.095% | -95.104% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon reviewing the financial statements of Virbac FR, a company operating within the pharmaceutical industry, the overall impression is positive. The company appears to be growing and has a strong financial position with an increasing trend in total assets, net income, and gross profit. Now, let's take a closer look at the pros and cons based on the provided data.
Increased Total Assets: Virbac FR's total assets have increased consistently over the past years (€1.11 billion in 2020, €1.20 billion in 2021, and €1.33 billion in 2022). This growth could indicate efficient management of the company's resources and successful investment strategies.
Growth in Gross Profit: The company has experienced a consistent increase in gross profit (€617.56 million in 2020, €712.85 million in 2021, and €794.99 million in 2022). This suggests Virbac FR's ability to generate more revenue while controlling the direct costs of producing their products.
